Clarivate Analytics, the global leader in providing trusted insights and analytics to accelerate the pace of innovation, announced today the launch of its annual "Drugs to Watch" report. The analysis identified 12 new drugs forecast to achieve annual sales of $1 billion or more (ie, blockbuster status) by 2022 using the Cortellis database, which includes information gathered from diverse sources including drug pipelines, patents, clinical trials, chemistry, deals and company announcements. More blockbuster drugs have been predicted to launch in 2018 than in any other year since the Drugs to Watch report began in 2013.
The drugs forecasted to launch in 2018 cover a wide range of therapeutic areas—ie, type 2 diabetes, endometriosis, childhood epilepsy, hemophilia, HIV, migraine, opioid addiction and shingles. Noteworthy examples on this list include:
|
Drug & company |
Disease & Impact |
|
Aimovig (erenumab) Amgen (USA) Novartis (Switzerland)
|
Migraine: Migraine is the third most common disease in the world, with an estimated global prevalence of 14.7% (ie, 1 in 7 people).1 Fewer than 50% of patients with migraine are satisfied with their current treatment. After little movement for many years, the migraine-prevention market is about to undergo a transformation with several new drugs, known as calcitonin gene-related peptide (CGRP) receptor inhibitor.
Aimovig (erenumab) has the potential to contribute to the transformation of the migraine market in 2018. |
|
Biktarvy (tenofovir alafenamide + emtricitabine + bictegravir) Gilead (USA) |
HIV infection: 37 million people globally are living with HIV; 21 million of whom receive antiretroviral therapy.2 While antiretroviral therapy does not cure HIV infection, it suppresses viral replication and allows an individual's immune system to strengthen and regain the capacity to fight off infections.
Expanding access to antiretroviral treatment is at the heart of a new set of targets for 2020, issued by the WHO, which aim to end the AIDS epidemic by 2030.2 Biktarvy offers an effective and simple treatment option for patients with HIV. |
|
Ozempic (semaglutide) Novo Nordisk (Denmark) |
Type 2 diabetes: More than 425 million people globally live with diabetes, 90% with type 2 diabetes. By 2045, this number is projected to rise to 629 million.3
Despite competing in a crowded market, Ozempic represents a new treatment that helps patients effectively control their blood sugar and significantly reduces the health risks commonly associated with diabetes—such as strokes and heart attacks. It is forecast to perform well due to its superior efficacy and safety versus competitor products. |
|
Shingrix (Zoster vaccine recombinant, adjuvanted)
GlaxoSmithKline (UK) |
Shingles: It's estimated around one in every four people will have at least one episode of shingles during their life.4 The only vaccine to make the list is GSK's Shingrix (Zoster vaccine recombinant, adjuvanted), which is set to become the market leading shingles vaccine. |
|
Sublocade (once-monthly buprenorphine)
Indivior (UK) |
Opioid dependence: More than 15 million people are living with opioid dependence worldwide.5 This disorder is ongoing and is rapidly evolving into a public health cris... Read More
Related News
From Molecule to Market: Innovations Accelerating the Future of Drug Development
Annie Roys September 4, 2025 Evotec and Eternygen to Develop Metabolic Disease Therapy
contractpharma January 11, 2017 Indicia Production Acquires METIS Biotechnologies
contractpharma January 11, 2017 You may like
Vacuum suction cup hanger steel plate high temperature aluminum plate suction cup titanium plate and other metal plate suction cup under 30 tons
Supply nitrile rubber suction cup HFG-200 vacuum suction cup spreader high temperature suction cup
3 tons of aluminum plate vacuum suction cup hanger can set high quality plate suction cup hanger
Tempered glass suction cup hanger, glass deep processing handling lifting suction cup, glass 90 degree flip suction crane
Orforglipron
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation! Subscribe
Note: You can unsubscribe from the alerts at any time. Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation! Subscribe
Note: You can unsubscribe from the alerts at any time. Most popular
The Rise of Biosimilars: Regulatory Pathways and Market Outlook
Nurah Ekhlaque
Sep 19, 2025
Basic Concepts and Latest Trends in Radiation Biology: Emerging Insights and Future Directions
Sadia Ajmal
Sep 18, 2025
Convert secures €13.6m grant to develop targeted chemo for oxygen-deprived tumours
pharmafile
Mar 12, 2018
New Products MORE
中文站-新建产品-en
High Temperature Banana Oil Magnetic Coupling Pump Set for Diesel Fuel
test-Product Name1
![]()
Cell Culture Flask
![]()
Aseptic Transfer Cap
![]()
SUS Aseptic Welder
|










(All Rights Reserved)